Nachrichten zur POOLBEG PHARMA LS -,0002 Aktie

FORM 8.5 (EPT/RI)…

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…

Jonathan Rowland increased his stake in fire suppression technology company Zenova Group (LON: ZED) to 7.8%. The share price rebounded…

Revolution Beauty (LON: REVB) has come to a confidential agreement with Chrysalis Investments (LON: CHRY) over the claims related to…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…

Poolbeg Pharma PLC (AIM:POLB) is already well down the path of establishing a rare disease company, said broker Shore Capital. “Lead…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has been granted a full patent in the United States for its drug candidate POLB…

Poolbeg Pharma has revealed a substantial year of progress in which the well-capitalised biopharmaceuticals company made strides forward in the…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has inked an exclusive 12-month option agreement to acquire a phase III-ready treatment from Silk Road...…

…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the US Patent Office has issued a Notice of Allowance for its immunomodulator II…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) executive chairman Cathal Friel has upped his stake in the company he co-founded. He bought 830,000…

In a recent discussion with Proactives Stephen Gunnion, Laura Maher, the newly appointed vice president of clinical operations at Poolbeg…

In a recent discussion with Proactives Stephen Gunnion, Laura Maher, the newly appointed vice president of clinical operations at Poolbeg…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced that co-founder Cathal Friel is stepping from non-executive to exective chairman, giving him...…

…

Equities analysts at Cavendish took notice of an eye-catching piece of research on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)’s flagship immunotherapy…

…

Poolbeg Pharma PLC has hailed research indicating a market opportunity exceeding $10 billion for its flagship asset, POLB 001, which has the…

…

A drug candidate being developed by Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has the potential to "revolutionise the impact of cancer immunotherapies",...…

Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) were marked higher after it unveiled significant progress with its AI-driven programme for…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said a poster presented by Dr Emma Searle, from The Christie Hospital, Manchester, highlighted the potential of...…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the departure of independent director Patrick Ashe, who, the company said, had been instrumental…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has received a patent grant from the Japanese Patent Office for its Immunomodulator II. This…

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the biopharma company specialising in diseases with high unmet medical needs, has announced its participation in...…

Shares in Poolbeg Pharma (LON: POLB) following yesterday’s announcement that there is evidence that POLB-001, which was developed as an…

In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former…

In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former…

…

…

Poolbeg Pharma has signed a strategic collaboration agreement with a Nasdaq-listed biopharmaceutical company to develop an optimised oral drug for…

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…